NHS: Drugs
Commons · Question 36736 · Tabled 10 Mar 2025 · Department of Health and Social Care · Official record
Answered 17 Mar 2025
Question
Asked by Preet Kaur Gill
To ask the Secretary of State for Health and Social Care, what performance improvement targets he has sought from the MHRA on bringing down the licensing backlog of generic and biosimilar medicine applications.
Answer
Answered by Karin Smyth, 17 Mar 2025
The Medicines and Healthcare products Regulatory Agency’s (MHRA) focus has been to ensure all applications received through all routes are processed on time. The MHRA has now embedded improvements in processing licencing applications into standard working...